Key facts
- It has raised $9.6M across 1 recorded rounds; the latest was Early Stage VC ($5.8M) in Nov 2022.
- Notable investors include 500 Global, Endeavor Catalyst, Raed Ventures, A15, Beltone Venture Capital — 10 tracked in total.
- Grinta has filed 2 Form Ds with the SEC since 2021, most recently Nov 2022 ($5.8M sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Grinta
Funding rounds
1 roundsAbout Grinta
Operator of a marketplace platform intended to modernize the pharmaceutical supply chain. The company works with all stakeholders, including manufacturers, distributors, wholesalers, and pharmacies across the pharmaceutical value chain to build a data-driven, reliable, and efficient pharmaceutical supply chain by integrating artificial intelligence and machine learning technologies on its platform, enabling customers with a user-friendly experience and giving access to the full spectrum of traceable and trackable pharmaceutical and medical products from multiple vendors.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Cairo, Egypt
- Founded
- 2021
- Employees
- 300
- Website
- grinta.ai/
- Ownership
- Privately Held (backing)
Grinta doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Grinta shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Grinta in its N-PORT filings yet. We sweep new filings monthly.